Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
It was originally used to treat type 2 diabetes, but now can be prescribed to help people lose weight too
Proven alternatives deliver comparable results with established safety: tirzepatide monotherapy produces 15-22% weight loss with FDA approval and extensive clinical data, while CagriSema (cagrilintide + semaglutide) delivers 15-25% weight loss with Phase 3 trial validation and clearer path to medical acceptance
)
PMID: 32532347 Mao Y, et al
Given MC4R targets several organ systems with various physiologic effects, including possible therapeutic roles in promoting weight loss and treating impotence, there are currently several MC4R agonists entering human clinical testing
These findings point to the benefits of tirzepatide in reducing cardiometabolic risk (Dani et al
US$ 24.61
US$ 22.54
US$ 22.75
US$ 23.92
US$ 28.86
